Jazz Pharmaceuticals
markets Epidiolex, the FDA-approved plant-derived CBD drug for severe childhood epilepsy, reporting 15% year-on-year sales growth in Q1 2026 as part of 19% overall company revenue growth.
- Country
- Ireland
- Ticker
- JAZZ
pharma
eu
Coverage
| CN | EU | US | |
|---|---|---|---|
| specialty-fine-chem | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biosynthetic cannabinoids (CBD & THC) | specialty-fine-chem | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.